A PYMNTS Company

Appeals Court Revives Regeneron’s Antitrust Lawsuit Against Novartis Over Vision Treatment

 |  March 18, 2024

The 2nd US Circuit Court of Appeals in Manhattan has breathed new life into an antitrust lawsuit brought by Regeneron Pharmaceuticals against Novartis. The lawsuit centers around prescription treatments aimed at addressing a condition that can result in severe eye disorders, potentially leading to permanent blindness.

The decision, rendered on Monday, marked a pivotal moment in the ongoing legal battle between the pharmaceutical giants. The appeals court ruled that a lower court judge had erred in dismissing Regeneron’s lawsuit, citing the incorrect application of legal standards to the claims put forth by the plaintiff.

The dispute between Regeneron and Novartis underscores the high stakes involved in the development and commercialization of treatments for critical medical conditions. At the heart of the lawsuit are allegations of anticompetitive behavior by Novartis, aimed at stifling competition and maintaining a dominant position in the market for prescription therapies targeting the identified eye disorder.

Read more: Paris Appeals Court Overturns Novartis, Roche $475M Antitrust Fine

The precise nature of the alleged antitrust violations has not been fully disclosed, but Regeneron’s contentions suggest a concerted effort by Novartis to undermine competition and impede the market entry of rival treatments. Such tactics, if proven, could have far-reaching implications for the pharmaceutical industry, particularly in the realm of specialized medications addressing complex medical needs.

Source: Reuters